Jci_page_head_homepage_01 Jci_page_head_homepage_02
Aniela Jakubowski, Christine Ambrose, Michael Parr, John M. Lincecum, Monica Z. Wang, Timothy S. Zheng, Beth Browning, Jennifer S. Michaelson, Manfred Baestcher, Bruce Wang, D. Montgomery Bissell, Linda C. Burkly
Published in Volume 115, Issue 9
J Clin Invest. 2005; 115(9):2330–2340 doi:10.1172/JCI23486
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 5

Ad-TWEAK administration in adult mice induces oval cell and biliary duct hyperplasia in the absence of significant liver damage. Mice were dosed with either Ad-TWEAK or Ad-control, as described in Methods, and livers were obtained 3 or 7 days later for TUNEL staining or 7 days later for H&E, A6, and CD34 staining. Serial frozen sections were stained with A6 or CD34 in order to assess marker coexpression. (AC) Ad-TWEAK treated mice. (A) H&E staining showing a marked oval cell and ductal hyperplasia. (B) Extensive A6 and (C) CD34 coexpression on oval cells and duct-like cells and on BECs. (DF) Ad-control–treated mice. (D) H&E staining showing an inflammatory response induced by Ad-control vector. (E) A6 and (F) CD34 coexpressed on bile ducts in the portal tract region and CD34 additionally expressed on vessels. Magnification, ×200. (G) Serum ALT measured in IU/l 3 days after adenoviral administration, showing no signs of liver damage. (H) TUNEL staining at days 3 and 7 after Ad-control or Ad-TWEAK administration. Magnification, ×400.